The accumulation of biomarker matched clinical outcomes data is one of the key bellwethers of a new diagnostic approaching the clinic. In recent years, we have seen a spike in outcomes data matched to spatial-biology and digital pathology markers, and few indicators of clinical proximity are as strong as the volume of data directly associated with biopharma clinical trials.
We recently analyzed the public domain for clinical trials and oncology conference abstracts (AACR, ASCO, ESMO, SITC) that included industry led spatial bio and / or digital pathology (DigPath) activity from 2020-H1 2022, the findings of which are summarized in a recent report. From this research, we identified ~90 clinical trials with evidence of prospective or retrospective spatial-bio / DigPath inclusion (Table 1), and further identified the subset of ~40 with matched outcomes data (Table 2).
Table 1. Summary of spatial-bio and / or DigPath clinical trials by indication and phase
Table 2. Summary of clinical trials where clinical outcomes data has either been published or is expected